Literature DB >> 17241689

Sorafenib-induced erythema multiforme.

Jennifer L MacGregor, David N Silvers, Marc E Grossman, William H Sherman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17241689     DOI： 10.1016/j.jaad.2006.10.981

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  9 in total

1.  Sorafenib-Induced Eruption Mimicking Erythema Multiforme.

Authors:  Dominique C Pichard; Adela R Cardones; Emily Y Chu; William L Dahut; Heidi H Kong
Journal:  JAMA Dermatol       Date:  2016-02       Impact factor: 10.282

2.  Erythema multiforme after treatment with sorafenib.

Authors:  Aaminah Faheem Azhar; Rachael Camille Saporito; Jordan Jamerson
Journal:  Proc (Bayl Univ Med Cent)       Date:  2021-03-08

3.  Sorafenib in the treatment of advanced hepatocellular carcinoma.

Authors:  Ali Ben Mousa
Journal:  Saudi J Gastroenterol       Date:  2008-01       Impact factor: 2.485

4.  Generalised erythematous skin eruptions induced by sorafenib: cutaneous toxicity and treatment outcome.

Authors:  Antonio Galán Brotons; Joaquín Borrás-Blasco; J Dolores Rosique-Robles; José María Vicent Verge; Md Elvira Casterá
Journal:  Clin Transl Oncol       Date:  2008-12       Impact factor: 3.405

Review 5.  Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review).

Authors:  Emily L Coleman; Brianna Olamiju; Jonathan S Leventhal
Journal:  Oncol Rep       Date:  2020-12-24       Impact factor: 3.906

6.  Sorafenib-associated facial acneiform eruption.

Authors:  Philip R Cohen
Journal:  Dermatol Ther (Heidelb)       Date:  2014-12-25

7.  Sorafenib induces delayed-onset cutaneous hypersensitivity: a case series.

Authors:  Kyoung Hee Sohn; Soo Yeon Oh; Kyung Whan Lim; Mi Yeong Kim; Suh Young Lee; Hye Ryun Kang
Journal:  Allergy Asthma Immunol Res       Date:  2014-03-05       Impact factor: 5.764

8.  The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics.

Authors:  Abel D Jarell; Donald Lawrence; Hensin Tsao
Journal:  Biologics       Date:  2007-12

9.  Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.

Authors:  Isamu Okamoto; Masaki Miyazaki; Ryotaro Morinaga; Hiroyasu Kaneda; Shinya Ueda; Yoshikazu Hasegawa; Taroh Satoh; Akira Kawada; Masahiro Fukuoka; Koichi Fukino; Takahiko Tanigawa; Kazuhiko Nakagawa
Journal:  Invest New Drugs       Date:  2009-09-18       Impact factor: 3.850
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.